8-K filing — Scienture Holdings, Inc. (SCNX)
Filed: 2026-08-20 AccNo: 0001493152-26-039474 Size: 344 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Scienture Announces Progress Towards Commercialization Of Its Arbli Oral Suspension Including Expanded Payor Coverage, Broader Pharmacy Access And New Channel Partnerships
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Scienture Holdings Q2 EPS $(0.07) Beats $(0.08) Estimate, Sales $343.639K Miss $1.964M Estimate
Scienture Holdings (NASDAQ:SCNX) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 85.42 percent increase over losses of $(0.48) per share
EXCLUSIVE: Scienture Launches Highest-Dose Naloxone Nasal Spray Rezenopy in US
Scienture launches Rezenopy, a 10 mg naloxone nasal spray for opioid overdoses, fulfilling initial U.S. wholesale orders.
EXCLUSIVE: Scienture Commences Commercial Launch and Fulfillment of Initial Rezenopy Orders; Targets Execution Through End of 2026 By Expanding Payer Coverage, Product Access, and Institutional Adoption